Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 12 | Journal of Ovarian Research

Fig. 12

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 12

Expression Levels at 8, 12, and 24 h. In Skov3 cells (a), GFP expression under the CMV promoter remains constant at 8, 12, and 24 h time points while p53-Bad* expression under CMV decreases significantly at each time point. Ovcar3 cells (b) display maximum expression of GFP at 12 h and p53-Bad* at 8 h. Kuramochi cells (c) show maximum expression of GFP at 12 h with no significant difference at 24 h, while p53-Bad* expression maximizes at 8 h and drops significantly at later time points. BJ cells (d) show no significant differences in GFP or p53-Bad* expression levels when compared across time points, though the p53-Bad* expression trends downward at longer time points compared to earlier. For each column n = 3 (except the Kuramochi 24 h time point, where n = 6), and the data were analyzed using 2-way ANOVA and Bonferroni’s post-test. Each *** corresponds to a P value < 0.001, each * to a P value < 0.05, and each “ns” to a non-significant P value

Back to article page